216 related articles for article (PubMed ID: 15657579)
1. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
2. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
Nguyen C; Faraggi M; Giraudet AL; de Labriolle-Vaylet C; Aparicio T; Rouzet F; Mignon M; Askienazy S; Sobhani I
J Nucl Med; 2004 Oct; 45(10):1660-8. PubMed ID: 15471830
[TBL] [Abstract][Full Text] [Related]
4. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
5. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
6. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
[TBL] [Abstract][Full Text] [Related]
7. [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma].
Gao ZR; An R; Zhang YX; Biersack HJ
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):621-4. PubMed ID: 17236560
[TBL] [Abstract][Full Text] [Related]
8. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
9. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma.
Hoefnagel CA; Delprat CC; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):334-6. PubMed ID: 1823851
[TBL] [Abstract][Full Text] [Related]
10. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
[TBL] [Abstract][Full Text] [Related]
11. [¹³¹I]Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies.
Rachh SH; Abhyankar S; Basu S
Nucl Med Commun; 2011 Dec; 32(12):1201-10. PubMed ID: 21968432
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
13. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
15. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
16. Role of [131I]metaiodobenzylguanidine therapy in carcinoids.
Hoefnagel CA; Taal BG; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):346-8. PubMed ID: 1726678
[TBL] [Abstract][Full Text] [Related]
17. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
Grünwald F; Ezziddin S
Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
[TBL] [Abstract][Full Text] [Related]
18. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
Makis W; McCann K; Bryanton M; McEwan AJ
Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
[TBL] [Abstract][Full Text] [Related]
19. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
20. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Christante D; Pommier S; Givi B; Pommier R
Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]